Positron emission tomography imaging in nonsmall-cell lung cancer

被引：19

作者：

Erasmus, Jeremy J.

Macapinlac, Homer A.

Swisher, Stephen G.

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Div Diagnost Imaging, Houston, TX 77030 USA

[2] Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Houston, TX 77030 USA

来源：

CANCER | 2007年 / 110卷 / 10期

关键词：

nonsmall-cell lung cancer (NSCLC); positron emission tomography (PET);

D O I：

10.1002/cncr.23051

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Positron emission tomography (PET) using 18F-2-deoxy-D-glucose, a D-glucose analog labeled with fluorine-18, complements conventional radiologic assessment in the evaluation of patients with nonsmall-cell lung cancer (NSCLC). PET is being routinely used to improve the detection of nodal and extrathoracic metastases. PET is also currently being evaluated in the assessment of prognosis and therapeutic response and by potentially allowing an earlier assessment of response may prove invaluable in the oncologic management of patients. The article discusses the diagnosis, staging, and assessment of treatment response and prognosis with an emphasis on the appropriate clinical use of PET in management.

引用

页码：2155 / 2168

页数：14

共 94 条

[1]

Ahuja V, 1998, CANCER, V83, P918, DOI 10.1002/(SICI)1097-0142(19980901)83:5<918::AID-CNCR17>3.3.CO

[2]

2-#

[3]

[Anonymous], 1997, AM J RESP CRIT CARE, V156, P320

[4] Non-small cell lung cancer: Dual-modality PET/CT in preoperative staging [J].